Cargando…
Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG
A small fraction of recipients who receive polyethylene-glycol (PEG)-containing COVID-19 mRNA-LNP vaccines (Comirnaty and Spikevax) develop hypersensitivity reactions (HSRs) or anaphylaxis. A causal role of anti-PEG antibodies (Abs) has been proposed, but not yet been proven in humans. We used ELISA...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239905/ https://www.ncbi.nlm.nih.gov/pubmed/37330369 http://dx.doi.org/10.1016/j.vaccine.2023.06.009 |
_version_ | 1785053599415402496 |
---|---|
author | Kozma, Gergely Tibor Mészáros, Tamás Berényi, Petra Facskó, Réka Patkó, Zsófia Oláh, Csaba Zs. Nagy, Adrienne Fülöp, Tamás Gyula Glatter, Kathryn Anne Radovits, Tamás Merkely, Béla Szebeni, János |
author_facet | Kozma, Gergely Tibor Mészáros, Tamás Berényi, Petra Facskó, Réka Patkó, Zsófia Oláh, Csaba Zs. Nagy, Adrienne Fülöp, Tamás Gyula Glatter, Kathryn Anne Radovits, Tamás Merkely, Béla Szebeni, János |
author_sort | Kozma, Gergely Tibor |
collection | PubMed |
description | A small fraction of recipients who receive polyethylene-glycol (PEG)-containing COVID-19 mRNA-LNP vaccines (Comirnaty and Spikevax) develop hypersensitivity reactions (HSRs) or anaphylaxis. A causal role of anti-PEG antibodies (Abs) has been proposed, but not yet been proven in humans. We used ELISA for serial measurements of SARS-CoV-2 neutralizing Ab (anti-S) and anti-PEG IgG/IgM Ab levels before and after the first and subsequent booster vaccinations with mRNA-LNP vaccines in a total of 291 blood donors. The HSRs in 15 subjects were graded and correlated with anti-PEG IgG/IgM, just as the anti-S and anti-PEG Ab levels with each other. The impacts of gender, allergy, mastocytosis and use of cosmetics were also analyzed. Serial testing of two or more plasma samples showed substantial individual variation of anti-S Ab levels after repeated vaccinations, just as the levels of anti-PEG IgG and IgM, which were over baseline in 98–99 % of unvaccinated individuals. About 3-4 % of subjects in the strongly left-skewed distribution had 15–45-fold higher values than the median, referred to as anti-PEG Ab supercarriers. Both vaccines caused significant rises of anti-PEG IgG/IgM with >10-fold rises in about ∼10 % of Comirnaty, and all Spikevax recipients. The anti-PEG IgG and/or IgM levels in the 15 vaccine reactors (3 anaphylaxis) were significantly higher compared to nonreactors. Serial testing of plasma showed significant correlation between the booster injection-induced rises of anti-S and anti-PEG IgGs, suggesting coupled anti-S and anti-PEG immunogenicity. Conclusions: The small percentage of people who have extreme levels of anti-PEG Ab in their blood may be at increased risk for HSRs/anaphylaxis to PEGylated vaccines and other PEGylated injectables. This risk might be further increased by the anti-PEG immunogenicity of these vaccines. Screening for anti-PEG Ab “supercarriers” may help predicting reactors and thus preventing these adverse phenomena. |
format | Online Article Text |
id | pubmed-10239905 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102399052023-06-05 Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG Kozma, Gergely Tibor Mészáros, Tamás Berényi, Petra Facskó, Réka Patkó, Zsófia Oláh, Csaba Zs. Nagy, Adrienne Fülöp, Tamás Gyula Glatter, Kathryn Anne Radovits, Tamás Merkely, Béla Szebeni, János Vaccine Article A small fraction of recipients who receive polyethylene-glycol (PEG)-containing COVID-19 mRNA-LNP vaccines (Comirnaty and Spikevax) develop hypersensitivity reactions (HSRs) or anaphylaxis. A causal role of anti-PEG antibodies (Abs) has been proposed, but not yet been proven in humans. We used ELISA for serial measurements of SARS-CoV-2 neutralizing Ab (anti-S) and anti-PEG IgG/IgM Ab levels before and after the first and subsequent booster vaccinations with mRNA-LNP vaccines in a total of 291 blood donors. The HSRs in 15 subjects were graded and correlated with anti-PEG IgG/IgM, just as the anti-S and anti-PEG Ab levels with each other. The impacts of gender, allergy, mastocytosis and use of cosmetics were also analyzed. Serial testing of two or more plasma samples showed substantial individual variation of anti-S Ab levels after repeated vaccinations, just as the levels of anti-PEG IgG and IgM, which were over baseline in 98–99 % of unvaccinated individuals. About 3-4 % of subjects in the strongly left-skewed distribution had 15–45-fold higher values than the median, referred to as anti-PEG Ab supercarriers. Both vaccines caused significant rises of anti-PEG IgG/IgM with >10-fold rises in about ∼10 % of Comirnaty, and all Spikevax recipients. The anti-PEG IgG and/or IgM levels in the 15 vaccine reactors (3 anaphylaxis) were significantly higher compared to nonreactors. Serial testing of plasma showed significant correlation between the booster injection-induced rises of anti-S and anti-PEG IgGs, suggesting coupled anti-S and anti-PEG immunogenicity. Conclusions: The small percentage of people who have extreme levels of anti-PEG Ab in their blood may be at increased risk for HSRs/anaphylaxis to PEGylated vaccines and other PEGylated injectables. This risk might be further increased by the anti-PEG immunogenicity of these vaccines. Screening for anti-PEG Ab “supercarriers” may help predicting reactors and thus preventing these adverse phenomena. Elsevier Ltd. 2023-06-05 /pmc/articles/PMC10239905/ /pubmed/37330369 http://dx.doi.org/10.1016/j.vaccine.2023.06.009 Text en © 2023 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Kozma, Gergely Tibor Mészáros, Tamás Berényi, Petra Facskó, Réka Patkó, Zsófia Oláh, Csaba Zs. Nagy, Adrienne Fülöp, Tamás Gyula Glatter, Kathryn Anne Radovits, Tamás Merkely, Béla Szebeni, János Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG |
title | Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG |
title_full | Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG |
title_fullStr | Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG |
title_full_unstemmed | Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG |
title_short | Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG |
title_sort | role of anti-polyethylene glycol (peg) antibodies in the allergic reactions to peg-containing covid-19 vaccines: evidence for immunogenicity of peg |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239905/ https://www.ncbi.nlm.nih.gov/pubmed/37330369 http://dx.doi.org/10.1016/j.vaccine.2023.06.009 |
work_keys_str_mv | AT kozmagergelytibor roleofantipolyethyleneglycolpegantibodiesintheallergicreactionstopegcontainingcovid19vaccinesevidenceforimmunogenicityofpeg AT meszarostamas roleofantipolyethyleneglycolpegantibodiesintheallergicreactionstopegcontainingcovid19vaccinesevidenceforimmunogenicityofpeg AT berenyipetra roleofantipolyethyleneglycolpegantibodiesintheallergicreactionstopegcontainingcovid19vaccinesevidenceforimmunogenicityofpeg AT facskoreka roleofantipolyethyleneglycolpegantibodiesintheallergicreactionstopegcontainingcovid19vaccinesevidenceforimmunogenicityofpeg AT patkozsofia roleofantipolyethyleneglycolpegantibodiesintheallergicreactionstopegcontainingcovid19vaccinesevidenceforimmunogenicityofpeg AT olahcsabazs roleofantipolyethyleneglycolpegantibodiesintheallergicreactionstopegcontainingcovid19vaccinesevidenceforimmunogenicityofpeg AT nagyadrienne roleofantipolyethyleneglycolpegantibodiesintheallergicreactionstopegcontainingcovid19vaccinesevidenceforimmunogenicityofpeg AT fuloptamasgyula roleofantipolyethyleneglycolpegantibodiesintheallergicreactionstopegcontainingcovid19vaccinesevidenceforimmunogenicityofpeg AT glatterkathrynanne roleofantipolyethyleneglycolpegantibodiesintheallergicreactionstopegcontainingcovid19vaccinesevidenceforimmunogenicityofpeg AT radovitstamas roleofantipolyethyleneglycolpegantibodiesintheallergicreactionstopegcontainingcovid19vaccinesevidenceforimmunogenicityofpeg AT merkelybela roleofantipolyethyleneglycolpegantibodiesintheallergicreactionstopegcontainingcovid19vaccinesevidenceforimmunogenicityofpeg AT szebenijanos roleofantipolyethyleneglycolpegantibodiesintheallergicreactionstopegcontainingcovid19vaccinesevidenceforimmunogenicityofpeg |